This trial is testing whether a combination of immunotherapy drugs and radiation therapy is more effective than radiation therapy alone in treating patients with liver cancer.
- Liver Cancer
- Stage IIIA Hepatocellular Carcinoma
- Stage IIIB Hepatocellular Carcinoma
- Stage IV Liver Cancer
- Stage IVA Hepatocellular Carcinoma
- Stage IVB Hepatocellular Carcinoma
- Stage III Liver Cancer
1 Primary · 4 Secondary · Reporting Duration: up to 24 months
Side Effects for
2 Treatment Groups
Arm I (hypofractionated RT, durvalumab)
1 of 2
Arm II (hypofractionated RT, durvalumab, tremelimumab)
1 of 2
30 Total Participants · 2 Treatment Groups
Primary Treatment: Durvalumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has Durvalumab been the focus of other scientific research projects in the past?
"There are a total of 345 clinical studies being conducted that focus on Durvalumab. Out of those, 51 have progressed to Phase 3 trials. The majority of these research projects are based in Cordoba, Texas; though, there are 13050 locations running studies for this treatment globally." - Anonymous Online Contributor
Are there any available vacancies for participants in this clinical trial?
"Yes, as of today this study is still looking for volunteers. According to the clinicaltrials.gov website, the listing was first created on February 4th, 2022 and updated November 7th, 2022." - Anonymous Online Contributor
How many participants are being allowed into this clinical trial?
"That is correct, the clinical trial listed on clinicaltrials.gov is still looking for patients to enroll. The study was first advertised on February 4th, and the most recent update was on November 7th. They are specifically recruiting 30 individuals from 1 site." - Anonymous Online Contributor
What is the most recent data on Durvalumab's safety profile?
"The Phase 2 clinical trial status of Durvalumab means that while there is some evidence supporting its safety, its efficacy has not been studied yet." - Anonymous Online Contributor
What are some of the most popular conditions that doctors treat with Durvalumab?
"Durvalumab is most commonly used to treat stage iii non-small cell lung cancer that cannot be removed surgically. Additionally, it can also be effective in treating metastatic urothelial carcinoma and advance directives." - Anonymous Online Contributor
Has this type of trial been done before?
"Since 2007, Durvalumab has undergone extensive clinical trials. The first one was completed in that same year and was sponsored by AstraZeneca. After the success of this initial study with 37 participants, Durvalumab received Phase 2 drug approval. Nowadays, there are 345 active trials for Durvalumab being conducted in 1325 cities and 58 countries across the globe." - Anonymous Online Contributor